media – Page 91 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Fosun Pharma’s HLX43 for injection receives approval from the U.S. FDA for clinical trials

On the evening of August 7, Fosun Pharma (600196) announced that its controlling subsidiary, Shanghai Henlius Biotech Co., Ltd., and its subsidiaries (collectively, ” Henlius “), have received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical trial of HLX43 for injection (a PD-L1-targeting antibody-drug conjugate) for the treatment of thymic carcinoma (TC). Henlius plans to conduct a global, multicenter clinical study for this indication in Australia, Japan, the United States, and other locations once conditions permit. The announcement shows that the new drug is an antibody-drug conjugate (ADC) targeting PD-L1, developed by Henlius by conjugating a new DNA topoisomerase I inhibitor small molecule toxin-peptide linker licensed by Henlius with an antibody targeting PD-L1 independently developed by Henlius. It is intended for the treatment of advanced/metastatic solid tumors. https://finance.eastmoney.com/a/202508073478916056.html
- Source: drugdu
- 201
- August 9, 2025
Haisco has been approved to conduct clinical trials of its independently developed HSK47388 tablets

August 7, Haisco(002653) issued an announcement that the company recently received the “Notice of Approval for Drug Clinical Trial” issued by the National Medical Products Administration, approving its independently developed innovative drugClinical trials are underway for HSK47388 tablets, a Class 1 chemical drug intended for the treatment of autoimmune diseases. According to the announcement, HSK47388 tablets demonstrated dose-dependent inhibition of inflammatory responses in preclinical studies, with good tolerability and safety, and are expected to provide a new treatment option for patients with autoimmune diseases. The company will continue to monitor the progress of this project and fulfill its corresponding information disclosure obligations. In the first quarter of 2025, Haisco achieved revenue of 892 million yuan and net profit attributable to shareholders of the parent company of 46.61 million yuan. https://finance.eastmoney.com/a/202508073478877223.html
- Source: drugdu
- 192
- August 9, 2025
Sino Biopharmaceutical’s Rovaxin tablets included in the breakthrough therapy program

On August 6, Sino Biopharmaceutical Co., Ltd. issued an announcement stating that the group’s independently developed rovacitinib tablets “TQ05105 (JAK/ROCK inhibitor)” have been included in the Breakthrough Therapy Drug Program (BTD) by the Drug Review Center of the China National Medical Products Administration (CDE) for the treatment of chronic graft-versus-host disease (cGVHD). This event indicates that the drug has significant advantages in treating chronic graft-versus-host disease and is expected to accelerate its approval and marketing. This will enhance the company’s future performance expectations, strengthen investor confidence, and further enhance the company’s competitiveness and valuation in the capital market. https://finance.eastmoney.com/a/202508063477733776.html
- Source: drugdu
- 185
- August 9, 2025
BeiGene achieves first half-year profit

On August 6, BeiGene announced its second-quarter 2025 US stock results and key semi-annual financial data for its A-share listings. In the first half of 2025, BeiGene achieved total operating revenue of 17.518 billion yuan, a year-on-year increase of 46.0%. Product revenue reached 17.360 billion yuan, a year-on-year increase of 45.8%. Net profit attributable to the parent company was 450 million yuan, marking the company’s first-half year return to profitability. These first-half results demonstrate significant breakthroughs in product sales and market expansion, which will significantly boost investor confidence, drive stock price appreciation, enhance the company’s valuation and attractiveness in the capital markets, and lay a solid foundation for future financing and development. https://finance.sina.com.cn/roll/2025-08-08/doc-infkfkhi3879307.shtml
- Source: drugdu
- 136
- August 8, 2025
Buchang Pharmaceuticals has appointed an exclusive distributor in the Philippines for a new drug

On August 7, Buchang Pharmaceutical issued an announcement stating that its controlling subsidiary Luzhou Buchang intends to sign an “Exclusive Supply Agreement” with the Philippine company GOODFELLOW, authorizing the latter to serve as the exclusive agent in the Philippines to complete the registration, related clinical trials, promotion, distribution and sales of the Class I new therapeutic biological drug – Efparepoetin alfa for injection. This transaction is another breakthrough in the internationalization process of Stepan Pharmaceutical’s strategic layout of biopharmaceuticals. While bringing economic benefits to the company, it will also help enhance the company’s brand value and have a good driving effect on enhancing the company’s core competitiveness. https://jnzstatic.cs.com.cn/zzb/htmlInfo/101481.html
- Source: drugdu
- 205
- August 8, 2025
Eli Lilly’s oral drug orforglipron (36 mg) resulted in an average weight loss of 12.4 kg

On August 7, Eli Lilly announced positive top-line results from the Phase 3 ATTAIN-1 clinical study. In ATTAIN-1, orforglipron achieved its primary endpoint, demonstrating significantly greater weight loss compared to placebo. At week 72, the highest dose (36 mg) of orforglipron achieved an average weight loss of 12.4 kg. These positive results are expected to bolster market confidence in Eli Lilly’s weight loss strategy, boost its valuation, and strengthen its position in future market competition, attracting greater investor attention. https://www.zhihuiya.com/news/info_10392.html
- Source: drugdu
- 112
- August 8, 2025
AI pharmaceutical leader wins big order worth 47 billion

Recently, Jingtai Technology announced that it has signed a pipeline collaboration agreement with DoveTree for a total order value of approximately HK$47 billion (US$5.99 billion), and has received an initial payment of approximately HK$400 million (US$51 million) as agreed in the agreement. This collaboration sets a new record for order size in the field of artificial intelligence (AI) and robotics-based new drug development. According to the terms of the agreement, Jingtai Technology and DoveTree have reached a cooperation on a number of large molecule and small molecule innovative drug assets in the preclinical stage, and will conduct new drug research and development for a series of DoveTree-designated targets. DoveTree exclusively enjoys the exclusive global development and commercialization rights of the relevant drugs. In return, in addition to the upfront payment, Jingtai Technology is entitled to receive a further payment of approximately HK$385 million (US$49 million), as well as potential milestone ...
- Source: drugdu
- 194
- August 8, 2025
Pfizer is brewing the next outbreak

Three years after the COVID-19 pandemic subsided, global pharmaceutical giant Pfizer has changed direction and is betting heavily on the next generation of anti-tumor therapies. Can it return to its peak? Q2 performance exceeded expectations, with revenue increasing by 10% year-on-year According to Pfizer’s latest financial report, its second-quarter 2025 revenue reached $14.7 billion, a 10% year-over-year increase, exceeding market expectations. Its first-half revenue reached $28.37 billion, a 1% year-over-year increase. Pfizer forecast full-year revenue of $61 billion to $64 billion and raised its 2025 full-year EPS guidance by $0.10 to a range of $2.90 to $3.10. From the perspective of business segments, Primary Care, Specialty Care and Oncology businesses generated revenues of US$5.54 billion (12%), US$4.378 billion (+7%) and US$4.387 billion (+11%) in the second quarter, respectively. Looking at specific products, within the Primary Care segment, the anticoagulant Eliquis (apixaban) contributed over $2 billion in Q2, a 6% year-over-year ...
- Source: drugdu
- 263
- August 8, 2025
【EXPERT Q&A】What precautions should be taken when conducting tests on the influencing factors of drug stability?

Drugdu.com expert’s response: The drug stability influencing factors test is a critical study that evaluates the quality changes of drugs under specific environmental conditions, aiming to provide a scientific basis for drug formulation design, packaging selection, storage condition determination, and expiry date setting. Its core considerations cover various aspects, including test design, condition control, sample management, testing and analysis, as well as data recording and reporting, as detailed below: I. Test Design Phase Clarify Test Objectives: Distinguish between influencing factors tests (e.g., high temperature, high humidity, intense light) and long-term stability tests or accelerated tests, clarifying the focus of each test (e.g., rapid screening of degradation pathways vs. prediction of long-term stability). Design targeted test protocols based on drug characteristics (e.g., chemical structure, dosage form, pH sensitivity). Select Representative Samples: Use samples (including both active pharmaceutical ingredients and formulations) that are consistent with actual production batch processes, avoiding laboratory-scale pilot samples. Ensure that sample ...
- Source: drugdu
- 253
- August 8, 2025
Medical Fair India

Organiser: Messe Düsseldorf GmbH (Germany) Time：March 26-28, 2026 address：NESCO Complex, Off Western Express Highway, Goregaon East, Mumbai, Maharashtra 400063, India Exhibition hall：Bombay Exhibition Center Product range: Medical Equipment: Medical electronic instruments, ultrasonic instruments, X-ray equipment, medical optical instruments, clinical laboratory analytical instruments, dental equipment and materials, hemodialysis equipment, respiratory equipment, hospital ward, operating room, and emergency room equipment, hospital office equipment, laboratory equipment, etc. Disposable Consumables: Disposable medical supplies, dressings and hygiene materials, various surgical instruments, etc. Medical Devices: Medical and health equipment, home health care products, physiotherapy, orthopedic technology, etc. Medical Peripherals: Information and communication technology, medical services, and publications, etc. About Medical Fair India： Medical Fair India is a professional trade exhibition for hospitals, medical devices, and equipment in India, and one of the most renowned exhibitions in the medical field in South and Central Asia. In recent years, the Indian medical industry has witnessed rapid ...
- Source: drugdu
- 244
- August 7, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.